Vactosertib - MedPacto

Drug Profile

Vactosertib - MedPacto

Alternative Names: EW-7197; NOV 1301; TEW-7197

Latest Information Update: 19 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ewha Womans University
  • Developer Case Comprehensive Cancer Center; MedPacto; National OncoVenture
  • Class Aniline compounds; Antineoplastics; Fluorine compounds; Imidazoles; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Transforming growth factor beta type I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Myelodysplastic syndromes
  • Phase I Multiple myeloma; Solid tumours

Most Recent Events

  • 17 Sep 2018 Samsung Medical Center plans a phase I/IIb trial for Pancreatic Cancer (Metastatic disease, Second-line therapy or greater) in September 2018 , (NCT03666832)
  • 14 Aug 2018 Chemical structure information added
  • 24 Jul 2018 MedPacto plans a phase Ib/IIa trial for Non-small cell lung cancer (Combination therapy, Metastatic disease) in South Korea in the second half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top